This Week in Obstetrics & Gynecology — Oct 15, 2026
Generated Oct 16, 2026 · 12:18
The week's practice-changing Obstetrics & Gynecology research, summarized for clinicians.
If the audio fails to play, refresh the page to renew the link.
Get next week’s Obstetrics & Gynecology briefing — free.
In your podcast app, or readable in your inbox with the audio one tap away.
Benzodiazepine Use Early in Pregnancy and Risk for Congenital Malformations.
Across more than four million insured pregnancies, first-trimester benzodiazepine exposure showed no meaningful increase in major malformations, with absolute risks around four percent in exposed and unexposed groups.
Annals of Internal Medicine · 2026 · PubMed
This week’s papers
- 01
Benzodiazepine Use Early in Pregnancy and Risk for Congenital Malformations.
Across more than four million insured pregnancies, first-trimester benzodiazepine exposure showed no meaningful increase in major malformations, with absolute risks around four percent in exposed and unexposed groups.
Fung K, Sujan AC, Bateman BT, et al. · Annals of Internal Medicine · 2026
From the briefingWe start in pregnancy, where several papers address what can be said with confidence to patients facing uncertainty in the first trimester and beyond. The headline paper comes from the Annals of Internal Medicine, where Fung and colleagues used two large United States insurance databases, Medicaid and MarketScan, to ask whether first-trimester benzodiazepine exposure raises the risk of major congenital malformations, a question on which prior data have been conflicting [1]. The cohort included more than four million pregnancies, with roughly fifty one thousand publicly insured and twenty eight thousand commercially insured pregnancies exposed. After propensity score weighting, the absolute risk of any major malformation was about four percent in exposed and unexposed pregnancies alike in Medicaid, and just under five percent in both groups in the commercial data, giving a pooled relative risk essentially equal to one. Organ-specific signals did not hold up across sensitivity analyses, there was no dose-response pattern, and individual benzodiazepines behaved similarly. The one loose thread is coexposure with other psychoactive medications, where some analyses showed elevated risks for selected malformations but without a consistent pattern, and the authors flag this for further study. The design is observational and limited to malformations recognized at birth in live-born infants, but the size and consistency of the result make this the strongest reassurance yet available for counselling patients exposed in early pregnancy.
If you only have time for one paper this week, make it the benzodiazepine malformation study from Fung and colleagues in the Annals of Internal Medicine [1]. It addresses a long-standing and genuinely conflicting question with enough scale and consistency to largely settle it for monotherapy, while clearly reopening the question of psychoactive coexposure.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 02
Growth trajectory and miscarriage diagnosis threshold in early IVF pregnancy: multicenter study.
In about ten thousand IVF pregnancies, an empty gestational sac at or beyond 47 days by transfer dating always predicted miscarriage, though external validation is still required.
Murugesu S, Richardson A, Shearer A, et al. · Ultrasound in Obstetrics & Gynecology · 2026
From the briefingStaying in the first trimester, Ultrasound in Obstetrics and Gynecology published a multicenter English cohort from Murugesu and colleagues examining just over ten thousand IVF pregnancies, where gestational age is known precisely from the date of embryo transfer [2]. About eighteen percent of these pregnancies were non-viable at the eleven to fourteen week scan. Viable pregnancies tended to have a larger crown-rump length for a given gestational age, but the distributions overlapped, and even among viable pregnancies there was wide physiological variability in crown-rump length and sac size. Mean crown-rump growth was a little under one millimetre per day. The striking finding is that an empty gestational sac at or beyond 47 days by transfer dating, seen in about four hundred pregnancies, was associated with miscarriage in every case, with perfect specificity and positive predictive value. The authors are explicit that this is a retrospective derivation and that external validation is needed before it could serve as a diagnostic threshold, but it offers a potentially earlier and more precise cut-off for this population than the general criteria built on uncertain dating.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 03
Cell-Free Fetal DNA Testing for Single Gene Conditions (Scientific Impact Paper No. 80).
Cell-free fetal DNA testing allows diagnosis of known familial single gene conditions from eight weeks without miscarriage risk, though NHS availability remains limited to selected scenarios.
Mone F, Holder-Espinasse M, Chandler NJ, et al. · BJOG · 2026
From the briefingA Scientific Impact Paper in BJOG from Mone and colleagues reviews cell-free fetal DNA testing for single gene conditions, distinguishing non-invasive prenatal diagnosis from the more familiar aneuploidy screening [3]. The paper notes that single gene conditions collectively affect about one in a hundred births, that testing can be done from eight weeks of gestation, and that when the familial variant is already known the result is considered diagnostic without invasive confirmation, sparing the roughly one in two hundred miscarriage risk attributed to amniocentesis or chorionic villus sampling. Its availability within the National Health Service is currently limited to selected scenarios, such as a previously affected child or suggestive ultrasound findings.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 04
Effectiveness of different methods of feticide: systematic review and meta-analysis.
Pooling over ten thousand feticide procedures, intracardiac potassium chloride failed in under half a percent of cases versus about eleven percent for intra-amniotic digoxin, with few complications.
Sorrenti S, Sacco A, Mone F, et al. · Ultrasound in Obstetrics & Gynecology · 2026
From the briefingAt the far end of prenatal care, a systematic review and meta-analysis by Sorrenti and colleagues, also in Ultrasound in Obstetrics and Gynecology, pooled 25 mostly observational studies covering more than ten thousand feticide procedures before second or third trimester termination [4]. Intracardiac potassium chloride failed to achieve asystole in under half a percent of cases, compared with about three percent for intrafunic potassium chloride, about five percent for intrafetal digoxin, and about eleven percent for intra-amniotic digoxin. Only four cases of chorioamnionitis were reported, and there was little evaluation of effects on postmortem examination beyond consistent cell lysis with intravascular lidocaine and potassium chloride. The authors conclude intracardiac potassium chloride appears most effective on point estimates, while noting that safety and feasibility in a given setting also shape the choice.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 05
2022 WHO estimates for overall and human papillomavirus test-based cervical cancer screening coverage worldwide: a review and synthetic analysis.
Only about a third of women aged 30 to 49 worldwide were screened for cervical cancer within five years, and just eight percent received HPV-based screening.
Serrano B, Roura E, Alemany L, et al. · The Lancet Global Health · 2027
From the briefingIn The Lancet Global Health, Serrano and colleagues provide the 2022 WHO estimates of screening coverage across more than two hundred countries and territories, including the first global assessment of HPV-based screening [5]. Only about a third of women aged 30 to 49 had been screened by any method in the previous five years, with coverage near three quarters in high-income countries but about a quarter in low and middle-income countries. HPV-based screening reached only about eight percent of women globally over five years, and roughly two percent in lower-income settings. Three in five women in this age group worldwide have never been screened, and more than nine in ten have never had an HPV test, leaving coverage far below the WHO target of seventy percent.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 06
How Would You Screen This 26-Year-Old Woman for Cervical Cancer? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
A primary care physician and gynecologist debate applying updated recommendations favouring primary HPV testing and self-collection, noting half of cervical cancers occur in underscreened or unscreened women.
Smith CC, Chelmow D, Freund KM, et al. · Annals of Internal Medicine · 2026
From the briefingCloser to the clinic, the Annals of Internal Medicine published a Beth Israel Deaconess grand rounds discussion led by Smith, with Chelmow and Freund among the authors, in which a primary care physician and an obstetrician-gynecologist debate how to screen a 26-year-old woman [6]. They frame the discussion around updated recommendations from the American Cancer Society, the Women's Preventive Services Initiative, and a draft United States Preventive Services Task Force update, all of which favour primary HPV testing and include self-collected specimens as an option. The discussion emphasizes that half of all cervical cancers occur in women who are underscreened or never screened, which links directly to the global data: self-collection and HPV-based strategies are framed in both papers as the main levers for reaching women who are currently missed, though this is expert opinion and modelling rather than new trial evidence.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 07
Impact of adjuvant treatment on survival in surgically staged 2009 FIGO stage I uterine serous carcinoma.
In stage I uterine serous carcinoma, chemotherapy was associated with better survival only when myoinvasion was present, and positive cytology marked poor prognosis in non-myoinvasive disease.
Graves SM, Yoh K, Sia TY, et al. · Gynecologic Oncology · 2026
From the briefingOur third theme covers treatment decisions in gynecologic oncology, fibroids, and menopause, where several papers temper enthusiasm for less intensive or adjunctive approaches. In Gynecologic Oncology, Graves and colleagues reviewed 327 patients with surgically staged FIGO 2009 stage I uterine serous carcinoma at a single institution [7]. Among patients with any myometrial invasion, adjuvant chemotherapy was associated with five-year overall survival of about eighty percent versus about fifty two percent without it, and in adjusted analyses chemotherapy roughly halved the risk of progression and of death. In patients without myoinvasion, chemotherapy did not appear to confer a survival benefit, but peritoneal cytology mattered a great deal: five-year progression-free survival was about ninety percent with negative cytology versus about half with positive cytology, outcomes resembling myoinvasive disease. The authors argue cytology status should enter adjuvant decision-making, a conclusion that rests on retrospective, single-center data subject to treatment selection bias.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 08
Effects of adjunctive metformin on recurrence-free survival and reproductive outcomes following progestin-based fertility-sparing treatment for endometrial neoplasia: Results from the FELICIA trial, a prospective, randomized, phase IIb trial with blinded central adjudication.
Adding metformin to medroxyprogesterone for fertility-sparing treatment of atypical hyperplasia or early endometrial cancer did not improve three-year recurrence-free survival or remission rates.
Mitsuhashi A, Yamagami W, Inaba Y, et al. · Gynecologic Oncology · 2026
From the briefingAlso in Gynecologic Oncology, the FELICIA trial from Mitsuhashi and colleagues randomized 154 women aged 18 to 42 with atypical endometrial hyperplasia or presumed early grade 1 endometrioid carcinoma to medroxyprogesterone acetate alone or combined with metformin at 750 or 1500 milligrams daily [8]. This was a negative trial: three-year recurrence-free survival was about forty five percent with and without metformin, and remission rates did not differ meaningfully. Live birth was numerically higher in the lower-dose metformin group among the 57 women attempting conception, but these are small exploratory numbers. Metformin added gastrointestinal side effects while reducing progestin-associated weight gain. The authors conclude it offers limited benefit in fertility-sparing treatment.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 09
Treatment Failure After Laparoscopic Radiofrequency Ablation Compared With Myomectomy.
Within two years, about fifteen percent of fibroid patients needed reintervention after laparoscopic radiofrequency ablation versus four percent after myomectomy, in nonrandomized prospective data.
Brito KS, Schembri M, Parvataneni R, et al. · Obstetrics & Gynecology · 2026
From the briefingFor fibroids, Obstetrics and Gynecology published an analysis by Brito and colleagues from the prospective ULTRA study comparing laparoscopic radiofrequency ablation with laparoscopic myomectomy [9]. Within two years, about fifteen percent of patients in the ablation group needed another procedure compared with about four percent after myomectomy, roughly four times the adjusted odds, and composite failure including persistent symptoms occurred in close to half of ablation patients versus about a quarter of myomectomy patients. Submucosal and laterally positioned fibroids were associated with ablation failure. The groups were not randomized and differed at baseline in age, body mass index, and parity, so residual confounding is possible, but the data inform counselling about durability.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 10
ACOG Clinical Practice Guideline: Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms.
ACOG issued GRADE-based recommendations on pharmacologic and nonpharmacologic management of menopausal vasomotor, sleep, and mood symptoms, with good practice points where evidence is insufficient.
American College of Obstetricians and Gynecologists · Obstetrics & Gynecology · 2026
The full briefing
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Obstetrics & Gynecology. This week we're covering 10 notable papers spanning medication safety and diagnostics in early pregnancy, the state of cervical cancer screening at home and worldwide, and treatment decisions in gynecologic oncology, fibroids, and menopause. Let's dive in.
We start in pregnancy, where several papers address what can be said with confidence to patients facing uncertainty in the first trimester and beyond. The headline paper comes from the Annals of Internal Medicine, where Fung and colleagues used two large United States insurance databases, Medicaid and MarketScan, to ask whether first-trimester benzodiazepine exposure raises the risk of major congenital malformations, a question on which prior data have been conflicting [1]. The cohort included more than four million pregnancies, with roughly fifty one thousand publicly insured and twenty eight thousand commercially insured pregnancies exposed. After propensity score weighting, the absolute risk of any major malformation was about four percent in exposed and unexposed pregnancies alike in Medicaid, and just under five percent in both groups in the commercial data, giving a pooled relative risk essentially equal to one. Organ-specific signals did not hold up across sensitivity analyses, there was no dose-response pattern, and individual benzodiazepines behaved similarly. The one loose thread is coexposure with other psychoactive medications, where some analyses showed elevated risks for selected malformations but without a consistent pattern, and the authors flag this for further study. The design is observational and limited to malformations recognized at birth in live-born infants, but the size and consistency of the result make this the strongest reassurance yet available for counselling patients exposed in early pregnancy.
Staying in the first trimester, Ultrasound in Obstetrics and Gynecology published a multicenter English cohort from Murugesu and colleagues examining just over ten thousand IVF pregnancies, where gestational age is known precisely from the date of embryo transfer [2]. About eighteen percent of these pregnancies were non-viable at the eleven to fourteen week scan. Viable pregnancies tended to have a larger crown-rump length for a given gestational age, but the distributions overlapped, and even among viable pregnancies there was wide physiological variability in crown-rump length and sac size. Mean crown-rump growth was a little under one millimetre per day. The striking finding is that an empty gestational sac at or beyond 47 days by transfer dating, seen in about four hundred pregnancies, was associated with miscarriage in every case, with perfect specificity and positive predictive value. The authors are explicit that this is a retrospective derivation and that external validation is needed before it could serve as a diagnostic threshold, but it offers a potentially earlier and more precise cut-off for this population than the general criteria built on uncertain dating.
Two further pieces broaden the prenatal picture. A Scientific Impact Paper in BJOG from Mone and colleagues reviews cell-free fetal DNA testing for single gene conditions, distinguishing non-invasive prenatal diagnosis from the more familiar aneuploidy screening [3]. The paper notes that single gene conditions collectively affect about one in a hundred births, that testing can be done from eight weeks of gestation, and that when the familial variant is already known the result is considered diagnostic without invasive confirmation, sparing the roughly one in two hundred miscarriage risk attributed to amniocentesis or chorionic villus sampling. Its availability within the National Health Service is currently limited to selected scenarios, such as a previously affected child or suggestive ultrasound findings. At the far end of prenatal care, a systematic review and meta-analysis by Sorrenti and colleagues, also in Ultrasound in Obstetrics and Gynecology, pooled 25 mostly observational studies covering more than ten thousand feticide procedures before second or third trimester termination [4]. Intracardiac potassium chloride failed to achieve asystole in under half a percent of cases, compared with about three percent for intrafunic potassium chloride, about five percent for intrafetal digoxin, and about eleven percent for intra-amniotic digoxin. Only four cases of chorioamnionitis were reported, and there was little evaluation of effects on postmortem examination beyond consistent cell lysis with intravascular lidocaine and potassium chloride. The authors conclude intracardiac potassium chloride appears most effective on point estimates, while noting that safety and feasibility in a given setting also shape the choice.
Our second theme is cervical cancer screening, where two papers show the distance between updated recommendations and actual reach. In The Lancet Global Health, Serrano and colleagues provide the 2022 WHO estimates of screening coverage across more than two hundred countries and territories, including the first global assessment of HPV-based screening [5]. Only about a third of women aged 30 to 49 had been screened by any method in the previous five years, with coverage near three quarters in high-income countries but about a quarter in low and middle-income countries. HPV-based screening reached only about eight percent of women globally over five years, and roughly two percent in lower-income settings. Three in five women in this age group worldwide have never been screened, and more than nine in ten have never had an HPV test, leaving coverage far below the WHO target of seventy percent. Closer to the clinic, the Annals of Internal Medicine published a Beth Israel Deaconess grand rounds discussion led by Smith, with Chelmow and Freund among the authors, in which a primary care physician and an obstetrician-gynecologist debate how to screen a 26-year-old woman [6]. They frame the discussion around updated recommendations from the American Cancer Society, the Women's Preventive Services Initiative, and a draft United States Preventive Services Task Force update, all of which favour primary HPV testing and include self-collected specimens as an option. The discussion emphasizes that half of all cervical cancers occur in women who are underscreened or never screened, which links directly to the global data: self-collection and HPV-based strategies are framed in both papers as the main levers for reaching women who are currently missed, though this is expert opinion and modelling rather than new trial evidence.
Our third theme covers treatment decisions in gynecologic oncology, fibroids, and menopause, where several papers temper enthusiasm for less intensive or adjunctive approaches. In Gynecologic Oncology, Graves and colleagues reviewed 327 patients with surgically staged FIGO 2009 stage I uterine serous carcinoma at a single institution [7]. Among patients with any myometrial invasion, adjuvant chemotherapy was associated with five-year overall survival of about eighty percent versus about fifty two percent without it, and in adjusted analyses chemotherapy roughly halved the risk of progression and of death. In patients without myoinvasion, chemotherapy did not appear to confer a survival benefit, but peritoneal cytology mattered a great deal: five-year progression-free survival was about ninety percent with negative cytology versus about half with positive cytology, outcomes resembling myoinvasive disease. The authors argue cytology status should enter adjuvant decision-making, a conclusion that rests on retrospective, single-center data subject to treatment selection bias.
Also in Gynecologic Oncology, the FELICIA trial from Mitsuhashi and colleagues randomized 154 women aged 18 to 42 with atypical endometrial hyperplasia or presumed early grade 1 endometrioid carcinoma to medroxyprogesterone acetate alone or combined with metformin at 750 or 1500 milligrams daily [8]. This was a negative trial: three-year recurrence-free survival was about forty five percent with and without metformin, and remission rates did not differ meaningfully. Live birth was numerically higher in the lower-dose metformin group among the 57 women attempting conception, but these are small exploratory numbers. Metformin added gastrointestinal side effects while reducing progestin-associated weight gain. The authors conclude it offers limited benefit in fertility-sparing treatment.
For fibroids, Obstetrics and Gynecology published an analysis by Brito and colleagues from the prospective ULTRA study comparing laparoscopic radiofrequency ablation with laparoscopic myomectomy [9]. Within two years, about fifteen percent of patients in the ablation group needed another procedure compared with about four percent after myomectomy, roughly four times the adjusted odds, and composite failure including persistent symptoms occurred in close to half of ablation patients versus about a quarter of myomectomy patients. Submucosal and laterally positioned fibroids were associated with ablation failure. The groups were not randomized and differed at baseline in age, body mass index, and parity, so residual confounding is possible, but the data inform counselling about durability. Finally, Obstetrics and Gynecology also published the new ACOG Clinical Practice Guideline on menopause-related vasomotor, sleep, and mood symptoms [10]. It applies a modified GRADE framework to pharmacologic and nonpharmacologic options for spontaneous and induced menopause at or beyond age 40, grading recommendations by strength and evidence quality and adding ungraded good practice points where evidence is lacking; the abstract does not detail the individual recommendations, so the full document is the place to see where the evidence is firm.
If you only have time for one paper this week, make it the benzodiazepine malformation study from Fung and colleagues in the Annals of Internal Medicine [1]. It addresses a long-standing and genuinely conflicting question with enough scale and consistency to largely settle it for monotherapy, while clearly reopening the question of psychoactive coexposure.
Here is what this week's evidence adds up to in Obstetrics & Gynecology. First, first-trimester benzodiazepine exposure on its own shows no meaningful increase in major malformations in a very large observational cohort, while coexposure with other psychoactive drugs remains unsettled. Second, an empty sac at 47 days after transfer dating may become a precise miscarriage threshold for IVF pregnancies, but it is a single retrospective derivation awaiting external validation. Third, guidelines now favour primary HPV testing and self-collection, yet global data show that most women aged 30 to 49 have never been screened and very few have had HPV testing. Fourth, in stage I uterine serous carcinoma, retrospective data link chemotherapy to better survival when myoinvasion is present and suggest positive cytology identifies higher-risk non-myoinvasive disease, though randomized evidence is lacking. Fifth, two treatment comparisons point away from lighter-touch options: metformin did not improve outcomes alongside progestin in fertility-sparing therapy, and radiofrequency ablation carried higher two-year failure than myomectomy in nonrandomized data.
That's your roundup for This Week in Obstetrics & Gynecology. The full transcript and references are available on the episode page. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.
This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.
Spot something worth flagging?
Get this every week in your podcast app — free.
New obstetrics_gynecology episodes land in your feed automatically — listen on your commute.